Inactive Instrument

InspireMD Stock price Nyse

Equities

Medical Equipment, Supplies & Distribution

Sales 2024 * 7.09M Sales 2025 * 14.65M Capitalization 55.59M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 7.84 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3.8 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.86%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 60 19-12-31
Director of Finance/CFO 62 11-03-30
Chief Tech/Sci/R&D Officer - 13-12-31
Members of the board TitleAgeSince
Director/Board Member 76 20-10-12
Chief Executive Officer 60 19-12-31
Director/Board Member 77 16-09-05
More insiders
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
More about the company